Rapid valve sterilization with meropenem plus ceftolozane/tazobactam combination therapy for <i>Pseudomonas aeruginosa</i> prosthetic valve endocarditis
The combination of meropenem and ceftolozane/tazobactam demonstrates promising synergy in physiologically relevant conditions, offering a potentially safer alternative for treating <i>P. aeruginosa</i> IE and stabilizing complex patients prior to cardiac surgery. Further clinical investigation is needed to evaluate its efficacy and safety profile in severe <i>Pseudomonas</i> infections, including IE.
Authors
- George Sakoulas (ORCID: https://orcid.org/0000-0002-6063-6217)
- Allen Jankeel (ORCID: https://orcid.org/0000-0003-1316-1332)
- Alaguvel Valliammai (ORCID: https://orcid.org/0000-0002-2578-1531)
- Warren E. Rose (ORCID: https://orcid.org/0000-0001-5012-5993)
- Gabriela Martinez (ORCID: https://orcid.org/0000-0003-4919-0733)
- Erlinda R. Ulloa (ORCID: https://orcid.org/0000-0002-0330-278X)
- Anuj K Khetarpal
- Zoe Hsiao
- Arianna Lorenzana
- Wendy A Tapia-Cano
Institutions
- Children's Hospital of Orange County (US)
- University of Wisconsin–Madison (US)
- University of California, Irvine (US)
- University of California San Diego (US)
- Sharp Rees-Stealy Medical Group (US)
Publication Details
- Journal
- JAC-Antimicrobial Resistance
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1093/jacamr/dlaf112
- Citations
- 2
- Primary Topic
- Infective Endocarditis Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Robert Wood Johnson Foundation
- Allergan
- National Institute of Allergy and Infectious Diseases
- National Center for Advancing Translational Sciences